A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
NCT ID: NCT02129075
Last Updated: 2021-11-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
60 participants
INTERVENTIONAL
2014-04-09
2018-05-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To determine whether the immune response to NY-ESO-1 elicited by vaccination with DEC-205/NY-ESO-1 fusion protein CDX-1401 (CDX-1401) plus polyinosinic-polycytidylic acid stabilized with poly-L-lysine and carboxymethylcellulose (poly-ICLC) is substantially increased by prior expansion in the number of circulating dendritic cells (DC) by therapy with recombinant Flt3 ligand (CDX-301) (fms-related tyrosine kinase 3 ligand \[Flt3L\]).
SECONDARY OBJECTIVES:
I. To assess the effect of the vaccine regimen on immune responses to other ongoing and nascent antitumor response antigens associated with melanoma (e.g., PRAME, MAGE-A3, p53, and gp100) as well as memory viral responses (influenza A) and chronic viral responses (cytomegalovirus \[CMV\], Epstein-Barr virus \[EBV\]).
II. To assess the effect of the vaccine regimen on the frequency and phenotypic character of peripheral blood mononuclear cell (PBMC) subsets including DCs, monocyte populations, T cells, and natural killer (NK) cells.
III. To assess the safety, tolerability, and clinical efficacy of the vaccine regimens.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive recombinant Flt3 ligand (CDX-301) subcutaneously (SC) on days -7 to -1, 1-3, and 22-28 of cycle 1 and only on days 1-3 of cycle 2. Patients also receive CDX-1401 SC or intradermally (ID) on day 1 of each cycle and poly-ICLC SC on days 1-2 of each cycle. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 4 and 12 weeks and then annually thereafter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (CDX-301, CDX-1401, poly-ICLC)
Patients receive recombinant Flt3 ligand (CDX-301) SC on days -7 to -1, 1-3, and 22-28 of cycle 1 and only on days 1-3 of cycle 2. Patients also receive CDX-1401 SC or ID on day 1 of each cycle and poly-ICLC SC on days 1-2 of each cycle. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Given SC or ID
Poly ICLC
Given SC
Recombinant Flt3 Ligand
Given SC
Arm II (CDX-1401, poly-ICLC)
Patients receive CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Given SC or ID
Poly ICLC
Given SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Given SC or ID
Poly ICLC
Given SC
Recombinant Flt3 Ligand
Given SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients may have had primary cutaneous, mucosal, or ocular melanoma or metastasis from an unknown primary site.
* Tissue should be submitted for evaluation of NY-ESO-1 expression and T-cell infiltrates. However, availability of tissue and/or positivity for NY-ESO-1 is not mandatory.
* Prior radiation, chemotherapy or biologics NOT allowed
* Not currently receiving any anticancer therapy
* Age \>= 18 years
* Because no dosing or adverse event (AE) data are currently available on the use of CDX-1401 or CDX-301 in patients \< 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.
* Eastern Cooperative Oncology Group (ECOG) performance score of 0-1
* Life expectancy of at least 6 months
* Leukocytes \>= 3,000/mcL
* Absolute neutrophil count \>= 1,000/mcL
* Platelets \>= 75,000/mcL
* Hemoglobin \> 9 g/dL
* Total bilirubin \< 1.5 x institutional upper limit of normal (bilirubin \< 3 x institutional upper limit of normal for Gilbert's syndrome)
* Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional upper limit of normal
* Creatinine \< 1.5 x institutional upper limit of normal OR creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal
* The first six patients enrolled in the Flt3L arm of the study cannot be human immunodeficiency virus (HIV)-positive. After the evaluation of safety in the first 6 patients, HIV-positive patients with adequate immune function as evidenced by stable CD4 counts \>= 350/mm\^3 are allowed to participate if the following criteria are met:
* maintained on stable antiretroviral therapy with no significant drug interactions, and
* no recent history of acquired immunodeficiency syndrome (AIDS) indicator conditions (\> 2 years from enrolling in trial), and
* physician providing patient's care for HIV must also approve of patient entering the study
* Females of childbearing potential must have a negative pregnancy test within 7 days before the initiation of protocol therapy.
* The effects of CDX-1401 or CDX-301 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) before study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception before the study, for the duration of study participation, and 4 months after completion of CDX-1401 or CDX-301 administration.
* NOTE: Subjects are considered not of child-bearing potential if they are surgically sterile, they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy, or they are postmenopausal. Menopause is the age associated with complete cessation of menstrual cycles, menses, and implies the loss of reproductive potential. By a practical definition, it assumes menopause after 1 year without menses with an appropriate clinical profile at the appropriate age.
* Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria
* Immunosuppressive therapy within 30 days prior to initiation of protocol therapy
* Steroid therapy, or steroid therapy with more than 7 consecutive days of steroids within the prior 4 weeks
* The use of prednisone or equivalent \< 0.125 mg/kg/day (absolute maximum of 10 mg/day) as replacement therapy is permitted
* Inhaled or topical corticosteroids are permitted
* Patients who are receiving any other investigational agents
* Current or history of systemic autoimmune disease requiring systemic therapy.
* NOTE: The following will not be exclusionary:
* The presence of laboratory evidence of autoimmune disease (e.g., positive antinuclear antibody \[ANA\] titer) without associated symptoms
* Clinical evidence of vitiligo
* Other forms of depigmenting illness
* Cardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association Class III or IV), active angina pectoris, or recent myocardial infarction (within the last 6 months)
* Cirrhosis or chronic hepatitis C virus positivity or chronic hepatitis B infection
* NOTE: A positive hepatitis B serology indicative of previous immunization (i.e., hepatitis B virus surface antibody \[HBsAb\]-positive and hepatitis B virus core antibody \[HBcAb\]-negative), or a fully resolved acute hepatitis B virus infection is not an exclusion criterion
* Known history of immunodeficiency disorder other than HIV-positive status
* Extensive active brain disease including symptomatic brain metastases or presence of leptomeningeal disease
* NOTE: Patients with brain metastasis, after definitive therapy with surgery or stereotactic radiation and stable off steroids for \>= 4 weeks, are eligible
* Other invasive cancers that are clinically active
* Pregnancy or nursing or unwilling to take adequate birth control during therapy
* NOTE: Pregnant women are excluded from this study because CDX-1401 or CDX-301 and poly-ICLC have an unknown potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CDX-1401 or CDX-301, breastfeeding should be discontinued if the mother is treated with CDX-1401 or CDX-301 and poly-ICLC
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to CDX-1401 or CDX-301 or poly-ICLC
* Prior organ allograft or allogeneic transplantation, if the transplanted tissue is still in place
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Medical or psychiatric illness that would, in the opinion of the investigator, preclude participation in the study or the ability of patients to provide informed consent for themselves
* History of pulmonary disease such as emphysema or chronic obstructive pulmonary disease (COPD) (forced expiratory volume in 1 second \[FEV1\] \< 60% of predicted for height and age). Pulmonary function tests (PFTs) are required in patients with prolonged smoking history or symptoms of respiratory dysfunction
* Vaccinations other than those given as part of this research study (with the exception of influenza vaccine) are prohibited throughout the duration of study participation.
* NOTE: Influenza vaccination (inactivated) is permitted during the flu season. The preferred time is 7 to 14 days after CDX-1401 administration
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nina Bhardwaj
Role: PRINCIPAL_INVESTIGATOR
Cancer Immunotherapy Trials Network
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, United States
Mount Sinai Hospital
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Providence Portland Medical Center
Portland, Oregon, United States
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bhardwaj N, Friedlander PA, Pavlick AC, Ernstoff MS, Gastman BR, Hanks BA, Curti BD, Albertini MR, Luke JJ, Blazquez AB, Balan S, Bedognetti D, Beechem JM, Crocker AS, D'Amico L, Danaher P, Davis TA, Hawthorne T, Hess BW, Keler T, Lundgren L, Morishima C, Ramchurren N, Rinchai D, Salazar AM, Salim BA, Sharon E, Vitale LA, Wang E, Warren S, Yellin MJ, Disis ML, Cheever MA, Fling SP. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nat Cancer. 2020 Dec;1(12):1204-1217. doi: 10.1038/s43018-020-00143-y. Epub 2020 Nov 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2014-00898
Identifier Type: REGISTRY
Identifier Source: secondary_id
CITN-07-FLT3L
Identifier Type: -
Identifier Source: secondary_id
CITN-07-FLT3L
Identifier Type: OTHER
Identifier Source: secondary_id
CITN-07-FLT3L
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2014-00898
Identifier Type: -
Identifier Source: org_study_id